Sorin Group Receives FDA Approval for the Mitroflow (TM) Aortic Heart Valve with New Phospholipid Reduction Treatment

Sorin Group, (MIL:SRN) (Reuters Code: SORN.MI), a global medical company
and a leader in the treatment of cardiovascular diseases, announced
today that it received U.S. Food and Drug Administration (FDA) approval
for the Mitroflow Aortic Pericardial Heart Valve with PRT.

The Phospholipid Reduction Treatment (PRT), a patented advanced tissue
treatment, is intended to further improve durability of the Mitroflow
bioprosthetic valve. Research has demonstrated that phospholipids play a
key role in the calcification process of bioprotheses. PRT has been
shown to decrease phospholipid content in pericardial tissue, which led
to a reduction of 99% of calcium uptake compared to control.

With over 30 years of clinical use and over 20 years of exceptional
peer-reviewed clinical outcomes, the Mitroflow valve has demonstrated
excellent hemodynamic performance due to its proven design. The addition
of PRT will help mitigate potential calcification and may further
improve the tissue valve’s clinically proven outstanding durability.

“I am excited to begin implanting the new Mitroflow with PRT,” said
Wilson Szeto, M.D., Cardiac Surgeon at the University of Pennsylvania
Medical Center in Philadelphia. “Mitroflow has a history of excellent
clinical results, and this treatment will help us to further improve the
durability of the valve for my patients.”

This enhancement demonstrates Sorin Group’s unwavering commitment to
innovation and improvement of its tissue heart valve portfolio. “We are
extremely pleased to receive FDA approval for the Mitroflow valve with
PRT”, said Michel Darnaud, President, Cardiac Surgery Business Unit,
Sorin Group. “There have been over 165,000 implants of Mitroflow valves
worldwide, and Mitroflow with PRT has been well received in Europe since
its launch in 2011. We trust the proven excellent performance of
Mitroflow and we are pleased to provide patients and cardiothoracic
surgeons with PRT which will potentially advance the valve’s proven
long-term durability.”

Sorin Group (
is a global, medical device company and a leader in the treatment of
cardiovascular diseases. The Company develops, manufactures, and markets
medical technologies for cardiac surgery and for the treatment of
cardiac rhythm disorders. With 3,750 employees worldwide,Sorin Group
focuses on two major therapeutic areas: Cardiac Surgery (cardiopulmonary
products for open heart surgery and heart valve prostheses and repair
devices) and Cardiac Rhythm Management (pacemakers, defibrillators and
non invasive monitoring to diagnose arrhythmias and deliver
anti-arrhythmia therapies as well as cardiac resynchronization devices
for heart failure treatment). Every year, over one million patients are
treated with Sorin Group devices in more than 80 countries.

For more information, please visit

Based on 30-day animal model, Sorin Group 2011, data on

Tel: +39 02 69969785Mobile: +39 348
9792201Director, Corporate CommunicationsSorin Groupe-mail:
gabriele.mazzoletti@sorin.comorTel: +39 02 69969716Director, Investor RelationsSorin

Source: Sorin Group